Scholarlink

Background <p>Postpartum hemorrhage (PPH) is an obstetric emergency that contributes significantly to maternal morbidity and mortality globally and in India. Several treatment modalities are available to stop blood loss during the management of PPH; still, many patients need interventional procedures and the mortality remains high. Recently, a promising new treatment modality, recombinant activated factor VIIa (rFVIIa), has been approved by the Indian regulatory authority, CDSCO. rFVIIa is now being utilized in many tertiary care centers in India in the management of severe PPH.</p> Methods <p>This retrospective observational study compared the blood loss, requirement of blood products, and invasive procedures before and after rFVIIa administration in 38 patients of severe PPH from tertiary care center. rFVIIa was administered in patients with severe PPH after the failure of uterotonics.</p> Results <p>Bleeding completely stopped or decreased in 32 (84.21%) patients post-rFVIIa administration. rFVIIa administration resulted in a significant reduction in blood loss, from 1252.63&#xa0;ml before administration of rFVIIa to only 299.47&#xa0;ml post-administration (<i>P</i> &lt; 0.0001). Requirement of blood products significantly reduced from 6.63 units pre-administration to 2.92 units post-administration (<i>n</i> = 38) (<i>P</i> &lt; 0.001). No thromboembolic events were reported in 30&#xa0;days of follow-up.</p> Conclusion <p>The present study demonstrated that the use of rFVIIa in patients with severe PPH significantly reduced blood loss and the requirement of blood products. This study highlights the potential role of using rFVIIa in the management of severe PPH as it offers a rapid, noninvasive and a safe alternative when conventional medical and surgical interventions are insufficient to control the blood loss.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical Experience with rFVIIa in Severe Atonic PPH: A Retrospective Observational Study from a Tertiary Care Center in India

  • 期刊论文

  • 发表日期：

    2026年5月23日

查看全文
  • Radhika Phophaliya,
  • Rajani Nawal,
  • Garima Vyas,
  • Asha Verma,
  • Pragati Gupta,
  • Shreem Sharma

摘要

Background

Postpartum hemorrhage (PPH) is an obstetric emergency that contributes significantly to maternal morbidity and mortality globally and in India. Several treatment modalities are available to stop blood loss during the management of PPH; still, many patients need interventional procedures and the mortality remains high. Recently, a promising new treatment modality, recombinant activated factor VIIa (rFVIIa), has been approved by the Indian regulatory authority, CDSCO. rFVIIa is now being utilized in many tertiary care centers in India in the management of severe PPH.

Methods

This retrospective observational study compared the blood loss, requirement of blood products, and invasive procedures before and after rFVIIa administration in 38 patients of severe PPH from tertiary care center. rFVIIa was administered in patients with severe PPH after the failure of uterotonics.

Results

Bleeding completely stopped or decreased in 32 (84.21%) patients post-rFVIIa administration. rFVIIa administration resulted in a significant reduction in blood loss, from 1252.63 ml before administration of rFVIIa to only 299.47 ml post-administration (P < 0.0001). Requirement of blood products significantly reduced from 6.63 units pre-administration to 2.92 units post-administration (n = 38) (P < 0.001). No thromboembolic events were reported in 30 days of follow-up.

Conclusion

The present study demonstrated that the use of rFVIIa in patients with severe PPH significantly reduced blood loss and the requirement of blood products. This study highlights the potential role of using rFVIIa in the management of severe PPH as it offers a rapid, noninvasive and a safe alternative when conventional medical and surgical interventions are insufficient to control the blood loss.